S&P 500   5,258.04 (+0.18%)
DOW   39,823.15 (+0.16%)
QQQ   444.94 (+0.02%)
AAPL   172.17 (-0.66%)
MSFT   421.32 (-0.03%)
META   489.15 (-0.95%)
GOOGL   151.22 (+0.23%)
AMZN   180.60 (+0.43%)
TSLA   175.83 (-2.22%)
NVDA   904.89 (+0.26%)
NIO   4.50 (-3.64%)
AMD   180.36 (+0.43%)
BABA   72.45 (+1.20%)
T   17.67 (+0.68%)
F   13.27 (+1.61%)
MU   117.92 (-1.02%)
CGC   8.88 (-7.02%)
GE   175.91 (-2.34%)
DIS   122.40 (+1.17%)
AMC   3.68 (-15.21%)
PFE   27.88 (+0.36%)
PYPL   67.26 (+1.04%)
XOM   116.23 (+1.10%)
S&P 500   5,258.04 (+0.18%)
DOW   39,823.15 (+0.16%)
QQQ   444.94 (+0.02%)
AAPL   172.17 (-0.66%)
MSFT   421.32 (-0.03%)
META   489.15 (-0.95%)
GOOGL   151.22 (+0.23%)
AMZN   180.60 (+0.43%)
TSLA   175.83 (-2.22%)
NVDA   904.89 (+0.26%)
NIO   4.50 (-3.64%)
AMD   180.36 (+0.43%)
BABA   72.45 (+1.20%)
T   17.67 (+0.68%)
F   13.27 (+1.61%)
MU   117.92 (-1.02%)
CGC   8.88 (-7.02%)
GE   175.91 (-2.34%)
DIS   122.40 (+1.17%)
AMC   3.68 (-15.21%)
PFE   27.88 (+0.36%)
PYPL   67.26 (+1.04%)
XOM   116.23 (+1.10%)
S&P 500   5,258.04 (+0.18%)
DOW   39,823.15 (+0.16%)
QQQ   444.94 (+0.02%)
AAPL   172.17 (-0.66%)
MSFT   421.32 (-0.03%)
META   489.15 (-0.95%)
GOOGL   151.22 (+0.23%)
AMZN   180.60 (+0.43%)
TSLA   175.83 (-2.22%)
NVDA   904.89 (+0.26%)
NIO   4.50 (-3.64%)
AMD   180.36 (+0.43%)
BABA   72.45 (+1.20%)
T   17.67 (+0.68%)
F   13.27 (+1.61%)
MU   117.92 (-1.02%)
CGC   8.88 (-7.02%)
GE   175.91 (-2.34%)
DIS   122.40 (+1.17%)
AMC   3.68 (-15.21%)
PFE   27.88 (+0.36%)
PYPL   67.26 (+1.04%)
XOM   116.23 (+1.10%)
S&P 500   5,258.04 (+0.18%)
DOW   39,823.15 (+0.16%)
QQQ   444.94 (+0.02%)
AAPL   172.17 (-0.66%)
MSFT   421.32 (-0.03%)
META   489.15 (-0.95%)
GOOGL   151.22 (+0.23%)
AMZN   180.60 (+0.43%)
TSLA   175.83 (-2.22%)
NVDA   904.89 (+0.26%)
NIO   4.50 (-3.64%)
AMD   180.36 (+0.43%)
BABA   72.45 (+1.20%)
T   17.67 (+0.68%)
F   13.27 (+1.61%)
MU   117.92 (-1.02%)
CGC   8.88 (-7.02%)
GE   175.91 (-2.34%)
DIS   122.40 (+1.17%)
AMC   3.68 (-15.21%)
PFE   27.88 (+0.36%)
PYPL   67.26 (+1.04%)
XOM   116.23 (+1.10%)
NYSE:MED

Medifast (MED) Stock Price, News & Analysis

$38.50
+0.97 (+2.58%)
(As of 03:40 PM ET)
Today's Range
$37.50
$39.00
50-Day Range
$34.59
$56.96
52-Week Range
$34.09
$109.52
Volume
213,075 shs
Average Volume
386,492 shs
Market Capitalization
$419.65 million
P/E Ratio
4.23
Dividend Yield
N/A
Price Target
$61.00

Medifast MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
58.3% Upside
$61.00 Price Target
Short Interest
Bearish
19.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
-4.17
Upright™ Environmental Score
News Sentiment
0.34mentions of Medifast in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$159,850 Sold Last Quarter
Proj. Earnings Growth
40.45%
From $3.56 to $5.00 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.13 out of 5 stars

Consumer Staples Sector

39th out of 134 stocks

Miscellaneous Food Preparations & Kindred Products Industry

1st out of 4 stocks

MED stock logo

About Medifast Stock (NYSE:MED)

Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.

MED Stock Price History

MED Stock News Headlines

LifeMD Shares Come Back to Life on GLP-1 Business Growth (MED)
LifeMD stock is surging as the company is riding the GLP-1 trend to double-digit revenue growth and projections for 67% earnings growth in 2024
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Medifast: Cheap Valuation, Uncertain Future
MED Apr 2024 20.000 put
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
LifeMD, Inc.: LifeMD Reports Fourth Quarter 2023 Results
MED Jun 2024 52.500 call
Medifast Is Getting Attractive
MED Apr 2024 27.500 put
MED Nov 2024 52.500 put
Don't Get Near These 10%+ Dividend Yield Stocks
Medifast Full Year 2023 Earnings: EPS Misses Expectations
Medifast Shares Drop 16% After Lower 4Q Earnings
See More Headlines
Receive MED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2024
Today
3/28/2024
Next Earnings (Estimated)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Miscellaneous food preparations & kindred products
Sub-Industry
Personal Products
CUSIP
58470H10
Employees
634
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$61.00
High Stock Price Target
$82.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+59.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$99.42 million
Pretax Margin
12.01%

Debt

Sales & Book Value

Annual Sales
$1.07 billion
Cash Flow
$11.20 per share
Book Value
$18.50 per share

Miscellaneous

Free Float
10,672,000
Market Cap
$417.58 million
Optionable
Optionable
Beta
1.15
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Daniel R. ChardMr. Daniel R. Chard (Age 59)
    Executive Chairman & CEO
    Comp: $1.94M
  • Mr. James P. Maloney CPA (Age 56)
    Chief Financial Officer
    Comp: $823.91k
  • Mr. Anthony E. Tyree (Age 59)
    Chief Business Operations Officer
    Comp: $655.86k
  • Mr. Jason L. Groves Esq. (Age 53)
    Executive VP, General Counsel & Corporate Secretary
    Comp: $669.51k
  • Mr. Nicholas M. Johnson (Age 44)
    Chief Field Operations Officer
    Comp: $696.4k
  • Mr. Jonathan Barrett MacKenzie (Age 52)
    VP of Finance & Chief Accounting Officer
  • Mr. Steven Zenker
    Vice President of Investor Relations
  • Ms. Claudia C. Greninger (Age 51)
    Chief Human Resources Officer

MED Stock Analysis - Frequently Asked Questions

Should I buy or sell Medifast stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MED, but not buy additional shares or sell existing shares.
View MED analyst ratings
or view top-rated stocks.

What is Medifast's stock price target for 2024?

2 brokerages have issued 1 year price targets for Medifast's shares. Their MED share price targets range from $40.00 to $82.00. On average, they expect the company's share price to reach $61.00 in the next twelve months. This suggests a possible upside of 58.3% from the stock's current price.
View analysts price targets for MED
or view top-rated stocks among Wall Street analysts.

How have MED shares performed in 2024?

Medifast's stock was trading at $67.22 on January 1st, 2024. Since then, MED shares have decreased by 42.7% and is now trading at $38.54.
View the best growth stocks for 2024 here
.

When is Medifast's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our MED earnings forecast
.

How were Medifast's earnings last quarter?

Medifast, Inc. (NYSE:MED) released its quarterly earnings results on Tuesday, February, 20th. The specialty retailer reported $1.09 EPS for the quarter, beating the consensus estimate of $0.99 by $0.10. The specialty retailer earned $191.02 million during the quarter, compared to analysts' expectations of $184.17 million. Medifast had a trailing twelve-month return on equity of 56.06% and a net margin of 9.27%. The firm's revenue was down 43.4% compared to the same quarter last year. During the same period last year, the firm earned $3.70 EPS.

How often does Medifast pay dividends? What is the dividend yield for Medifast?

Medifast declared a quarterly dividend on Thursday, September 7th. Investors of record on Tuesday, September 19th will be given a dividend of $1.65 per share on Tuesday, November 7th. This represents a $6.60 annualized dividend and a yield of 17.13%. The ex-dividend date is Monday, September 18th.
Read our dividend analysis for MED
.

What guidance has Medifast issued on next quarter's earnings?

Medifast issued an update on its first quarter 2024 earnings guidance on Tuesday, February, 20th. The company provided EPS guidance of 0.250-0.950 for the period, compared to the consensus EPS estimate of 1.490. The company issued revenue guidance of $155.0 million-$175.0 million, compared to the consensus revenue estimate of $205.8 million.

What is Daniel Chard's approval rating as Medifast's CEO?

44 employees have rated Medifast Chief Executive Officer Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among the company's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medifast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

Who are Medifast's major shareholders?

Medifast's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (15.49%), Vanguard Group Inc. (15.48%), Pacer Advisors Inc. (4.80%), First Trust Advisors LP (3.65%), Dimensional Fund Advisors LP (2.85%) and Charles Schwab Investment Management Inc. (1.71%). Insiders that own company stock include Andrea B Thomas, Constance J Hallquist, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Jeffrey J Brown, Kevin G Byrnes and Scott Schlackman.
View institutional ownership trends
.

How do I buy shares of Medifast?

Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:MED) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners